Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

73.75EUR
5:00am EST
Change (% chg)

€0.55 (+0.75%)
Prev Close
€73.20
Open
€73.15
Day's High
€73.79
Day's Low
€73.15
Volume
283,261
Avg. Vol
2,118,891
52-wk High
€92.97
52-wk Low
€71.06

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €92,461.42
Shares Outstanding(Mil.): 1,263.13
Dividend: 2.96
Yield (%): 4.04

Financials

  Industry Sector
P/E (TTM): -- 32.98 16.42
EPS (TTM): -- -- --
ROI: -- 15.00 34.33
ROE: -- 16.53 17.15

French and Benelux stocks-Factors to watch on Jan 11

Jan 11 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.

Jan 11 2018

Sanofi and Regeneron boost investment in cancer drug cemiplimab

PARIS France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.

Jan 08 2018

Sanofi and Regeneron boost investment in cancer drug cemiplimab

PARIS, Jan 8 France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.

Jan 08 2018

BRIEF-Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 Palisade Trial Of AR101 For Peanut Allergy

* AIMMUNE THERAPEUTICS - PALISADE COMPLETED IN 2017; TOPLINE RESULTS ANTICIPATED IN FEBRUARY

Jan 08 2018

BRIEF-Sanofi And Alnylam Pharmaceuticals Enter Into Partnership

* AND ALNYLAM, ANNOUNCED ON SUNDAY STRATEGIC RESTRUCTURING OF RNAI THERAPEUTICS RARE DISEASE ALLIANCE

Jan 08 2018

Sanofi to market new hemophilia drug in deal with Alnylam

PARIS, Jan 8 French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals.

Jan 08 2018

BRIEF-Evotec, Apeiron Biologics receive milestone payment from Sanofi

* SAYS ‍EVOTEC AND APEIRON ACHIEVE FIRST MILESTONE IN IMMUNO-ONCOLOGY ALLIANCE WITH SANOFI​

Jan 08 2018

Philippines fines Sanofi, suspends clearance for Dengvaxia

MANILA The Philippines has fined Sanofi $2,000 and suspended clearance for the French drug maker's controversial dengue vaccine Dengvaxia, citing violations on product registration and marketing, its health secretary said on Thursday.

Jan 04 2018

Philippines fines Sanofi, suspends clearance for Dengvaxia

MANILA, Jan 4 The Philippines has fined Sanofi $2,000 and suspended clearance for the French drug maker's controversial dengue vaccine Dengvaxia, citing violations on product registration and marketing, its health secretary said on Thursday.

Jan 04 2018

BRIEF-Sanofi Joins Forces With BIOASTER To Improve The Search For Next-Generation Vaccine Candidates

* JOINS FORCES WITH BIOASTER TO IMPROVE THE SEARCH FOR NEXT-GENERATION VACCINE CANDIDATES Further company coverage: (Gdynia Newsroom)

Dec 21 2017

Earnings vs. Estimates